The latest at MBC Biolabs
The latest at MBC Biolabs
Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie
AbbVie, a leading global biopharmaceutical company, has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin's lead PINK1 compound.
ONO Entered Sponsorship Agreements with MBC BioLabs and LabCentral
This sponsorship will allow ONO to early access the most updated information of the biotech startups and others residing in LabCentral and MBC BioLabs facilities.
Cage Bio closes $7.2 million round of series A funding
The investment was led by professional and angel investor groups consisting of current and former pharmaceutical executives and physicians.
BigHat Biosciences Raises $19 Million in Series A Funding
BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, announced it has raised $19 million in an oversubscribed Series A funding round.
Charles River Announces Strategic Partnership with Cypre
The partnership will provide Charles River clients with access to Cypre’s proprietary 3D tumor model platform, Falcon-X™, which will expand Charles River’s 3D in vitro testing services to further optimize immuno-oncological approaches for its clients.
Biotech David Faces a Goliath
MBC BioLabs alum, Trevor Martin, is named Executive of the Year 2020 by San Francisco Business Times
XPose Therapeutics and Accelero Biostructures
XPose Therapeutics and Accelero Biostructures, two of the MBC BioLabs San Carlos resident companies, announced research agreements.
Biotech startups thrive in San Carlos nursery
Doug Crawford talks about how the biotech industry has largely been able to thrive amid the pandemic.
OneSkin launches topical senetherapeutic skin treatment
Symbiome, the first skincare brand to create a collection of BioIntact™ products to nourish the skin microbiome, has officially launched today.
Introducing Symbiome, the Future of Clean, Microbiome Skincare
Symbiome, the first skincare brand to create a collection of BioIntact™ products to nourish the skin microbiome, has officially launched today.
MBC BioLabs Congratulates Jennifer Doudna and Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry
Jennifer Doudna, also co-founder of Mammoth Biosciences, a MBC BioLabs alumni company, and Emmanuelle Charpentier are the first women to win a Nobel Prize in the sciences together.
Announcement of the Astellas Golden Ticket
EXTENDED! The competition is now open until Monday, November 2nd, 2020.
Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases
Siolta Therapeutics, a clinical-stage biotech company and MBC BioLabs San Carlos resident company, has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H.
Symbiome Raises $15M for ‘Ancestral Microbiome’ Skin Range
Symbiome is slated to launch Oct. 7 with seven products that aim to shift the skin’s microbiome back to its “ancestral” state, according to Larry Weiss, founder and chief scientific officer.
How MBH Architects helped a critical research facility get built during the lockdown
Andres Grechi, Principal and Design Director at MBH Architects, talks about his insights on how his team helped complete a facility that may prove to be a game-changer in the fight against the COVID-19
MBC BioLabs partners with SPARK
The SPARK program at Stanford is a partnership between Stanford researchers and volunteer experts from the biotechnology ecosystem that provides education and mentorship.
Project Profile: MBC BioLab
Online Lab Manager introduces 930 Brittan Ave in San Carlos
XPose Therapeutics embarks on the discovery and development of novel oncology medicines targeting DNA Damage Response with non-dilutive funding from NCI
XPose Therapeutics is leveraging 3D structures of molecular fragments bound to drug targets to develop specific therapeutics.
Announcement of the 2020 Golden Ticket sponsored by Servier
2020 Servier Golden Ticket will be awarded in early September!
Biotech Startup Discovers Novel Hand Sanitizer for COVID-19, Offering Long-lasting 4+ Hours of Protection
IonLAST™, a novel hand sanitizer, kills germs on contact and, unlike common hand sanitizers, provides protection against their transmission for more than four hours after applying to skin.
With $30M and Stanford immunotherapy pioneer, biotech eyes one of the toughest brain diseases
A Stanford University spinout is joining the small army of biotech companies trying to find drugs for amyotrophic lateral sclerosis (ALS).
Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology Approach to Treating Neurodegenerative and Aging-related Diseases
Tranquis Therapeutics are committed to the discovery and development of innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases.
Biotech startup announces R&D collaboration with major Japanese drug delivery company
The companies will evaluate novel formulations of drugs that have been notoriously difficult to formulate and deliver into the skin.
BioWorld: Drug developers’ Golden Ticket
BioWorld: Drug developers’ Golden Ticket, worth a lot more than a tour of a candy manufacturing plant